Evonile Pharma Limited Fixes ₹884.75 Crore Rights Issue Terms

On November 4, 2026, Evonile Pharma Limited fixed the terms of a ₹884.75 crore partly paid rights issue at ₹860 per share. Eligible shareholders on the November 11 record date will receive rights entitlements of five shares for every 12 shares held, with the issue scheduled from November 19 to December 3.

What are the final terms of Evonile Pharma's rights issue?

Evonile Pharma has set the rights issue at up to 10,287,832 partly paid-up equity shares priced at ₹860 each, taking the maximum issue size to ₹884.75 crore. The Rights Issue Committee finalised the terms at its meeting held on November 4, 2026, under authority delegated by the board.

The entitlement ratio is five rights shares for every 12 equity shares held by eligible shareholders on the record date. The company has fixed Wednesday, November 11, 2026, as the record date for determining rights entitlements. This date establishes which shareholders can receive and trade the entitlement associated with the offer, subject to the applicable process.

The issue will open on Thursday, November 19, 2026, and close on Thursday, December 3, 2026. The offer concerns partly paid-up shares with a face value of ₹5 each. The disclosed issue size is below the broader approval of up to ₹900 crore granted by the board in October.

How will shareholders pay for the partly paid rights shares?

Evonile Pharma has specified that ₹645 per rights share will be payable on application, while ₹215 per share will be payable on the first and final call. Together, these instalments equal the ₹860 issue price fixed for each partly paid-up equity share.

The structure means an applicant for the rights shares will not pay the entire issue price at the time of application. The later call amount remains part of the stated payment schedule approved alongside the Letter of Offer. Shareholders should rely on the offer documents and the prescribed application process for the operational terms of participation.

Partly paid-up rights issues are distinct from an immediate fully paid allotment because the issuer collects the issue price in stages. For investors, the disclosed application and call amounts are relevant to the cash commitment attached to each rights share. The company has not disclosed any alternative payment terms in the information provided.

How did Evonile Pharma reach this stage of the fund raise?

Evonile Pharma's board first approved raising up to ₹900 crore through a rights issue of partly paid-up equity shares at its meeting on October 8, 2026. The approval covered the proposed fund raise, while authority to settle key terms, including the price, ratio, timing and intermediaries, was delegated to a three-member Rights Issue Committee.

The committee comprises Vikas Gupta, Jagriti Gupta and Shashank Sinha, according to the disclosed board outcome. It subsequently set the final offer terms on November 4. The board also approved the Letter of Offer and related rights issue matters at its November 4 meeting.

BSE Limited granted in-principle approval in relation to the draft Letter of Offer, as disclosed by the company. Such approval is a stated regulatory milestone in the offer process, while the issue remains subject to the terms and procedures set out in the relevant offer documentation and applicable requirements.

What does the rights issue mean for Evonile Pharma investors?

The rights issue gives eligible Evonile Pharma shareholders an opportunity to subscribe in proportion to their holding at the disclosed 5:12 ratio. For shareholders who take up their entitlement, the transaction provides a route to maintain participation in the expanded equity base, subject to the final allotment and offer process.

For shareholders who do not subscribe, the issue increases the number of equity shares offered through the rights route. The actual ownership effect for any individual shareholder depends on their existing holding, the number of rights shares subscribed for and the outcome of the issue. The source material does not provide a post-issue shareholding calculation or projected earnings impact.

The company described the board-approved fund raise as being through partly paid-up shares, and reports cited the issue in the context of strategic growth. However, the supplied disclosures do not provide a detailed break-up of planned utilisation. Investors seeking to assess the financial impact will need to consider the Letter of Offer and subsequent company disclosures.

Why do the record date and offer timetable matter?

The November 11 record date is important because it determines the shareholders eligible for rights entitlements. The eight-day interval between the record date and the November 19 opening gives the market a defined timetable for the offer, while the December 3 closing date sets the final subscription deadline.

The offer follows disclosures made in a period when Evonile Pharma has been updating investors on its board decisions, committee outcome and BSE's in-principle approval. A clear sequence of approvals and dates helps shareholders track the transition from a broad board mandate of up to ₹900 crore to the final ₹884.75 crore issue terms.

For the broader pharmaceutical sector, the announcement is a company-specific capital raising event rather than evidence of an industry-wide funding trend. The supplied information does not state any sector-level market reaction, share-price movement, or customer and operational change resulting from the rights issue.

Conclusion

Evonile Pharma has moved from its October board approval to a defined partly paid rights offer worth up to ₹884.75 crore. The final terms specify the ₹860 price, 5:12 entitlement ratio, two-stage payment structure and key dates, giving eligible shareholders the factual framework needed to assess participation.

The next dates to watch are the November 11 record date, the November 19 issue opening and the December 3 closing. Investors can also monitor the Letter of Offer and any further exchange filings for additional details on the offer process, allotment and the stated use of proceeds.